Gilead Sciences Inc has stopped a Phase 2 study of the monocolonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. The decision was based on a recommendation of the study’s data monitoring committee. ---Subscribe to MedNous to access this article--- Company News Clinical Research
